Indeed, TRAIL has been considered as a promising anti-tumor agent with a strong clinical therapeutic potential [23, 24] and various studies demonstrated selective apoptotic effects of TRAIL on tumor cells including glioma cells and GSCs [25–29]. The gene discussed is TNFSF10; the disease is neoplasm.